What medication should be prescribed for a patient with dementia who has severe daytime and nighttime behavioral agitation and insomnia?

Pharmacological Management of Severe Behavioral Agitation and Insomnia in Dementia

For a patient with dementia experiencing severe daytime and nighttime behavioral agitation plus insomnia, initiate nonpharmacological interventions first, but if symptoms are severe, dangerous, or cause significant distress, start a low-dose antipsychotic (risperidone 0.25-0.5 mg or brexpiprazole 0.5-1 mg) for agitation, and consider adding a Z-drug hypnotic (eszopiclone) or low-dose orexin receptor antagonist (lemborexant 2.5 mg) specifically for the insomnia component after assessing for restless legs syndrome.

Stepwise Approach to Treatment

Step 1: Assessment Before Medication

Before prescribing any medication, you must assess for:

• Pain and modifiable contributors to agitation (infection, constipation, medication side effects) 1
• Restless legs syndrome (RLS) - a commonly missed, treatable cause of nighttime agitation and insomnia in dementia that responds to gabapentin enacarbil 2
• Pattern and timing of symptoms to distinguish true agitation from sleep-related behaviors 1
• Baseline quantitative measures using tools like Cohen-Mansfield Agitation Inventory to track response 1

Step 2: Nonpharmacological Interventions

The APA guidelines mandate reviewing nonpharmacological interventions before antipsychotic use in nonemergency situations 1. However, given the severity described ("severe behavioral issues"), you likely meet criteria for pharmacological intervention.

Step 3: Pharmacological Treatment for Agitation

Antipsychotic therapy is indicated when:

• Symptoms are severe, dangerous, or cause significant distress 1
• This clearly applies to your patient with "severe behavioral issues"

First-line antipsychotic options:

• Risperidone: Most robust evidence base, showing significant efficacy for aggression and psychosis (OR 1.96; 95% CI 1.49-2.59) 3. Start at 0.25-0.5 mg daily, titrate to minimum effective dose (typically 0.5-2 mg/day) 1, 4

• Brexpiprazole: FDA-approved specifically for agitation in Alzheimer's dementia, showing approximately 5-point greater reduction on CMAI compared to placebo at 12 weeks 5. Start 0.5-1 mg daily, target 2-3 mg/day 5, 6. Particularly effective in patients with co-occurring sleep disturbance 6

Alternative considerations:

• SSRIs (citalopram): Moderate efficacy for agitation (OR 1.61; 95% CI 1.02-2.53), safer profile than antipsychotics 3, 4
• Dextromethorphan/quinidine: Strong efficacy (OR 3.04) but based on limited trials 3

Avoid:

• Haloperidol: Inferior efficacy compared to all comparators 3

Step 4: Addressing the Insomnia Component

The insomnia requires separate consideration beyond agitation management:

First-line for insomnia in dementia:

• Eszopiclone (Z-drug): Most favorable evidence, significantly improving sleep efficiency and latency with small-to-large effect sizes 7. Start 1-2 mg at bedtime

• Lemborexant 2.5 mg: Low-dose orexin receptor antagonist showing best profile for reducing nocturnal awakenings, meeting clinical benchmarks 7

• Zolpidem: Historical evidence in dementia-related insomnia, start 5 mg, may titrate to 10-15 mg 8. However, eszopiclone has more recent supportive data 7

Alternative approach:

• Gabapentin enacarbil: If RLS is identified as contributing factor, this addresses both nighttime agitation AND insomnia (48.45 minutes increased total sleep time, p=0.026) 2

Step 5: Critical Safety Discussions

Before initiating antipsychotics, you must:

• Discuss with patient (if feasible) and surrogate decision-maker the increased mortality risk associated with antipsychotics in dementia 1, 5
• Document risk-benefit assessment in medical record 1
• Explain this is for severe symptoms where benefits may outweigh risks

Common adverse effects to monitor:

• Brexpiprazole: dizziness, headaches, somnolence, UTIs 5
• Risperidone: extrapyramidal symptoms, sedation, cerebrovascular events 4
• Z-drugs: falls risk (trend toward more falls with gabapentin enacarbil, p=0.066) 2

Step 6: Monitoring and Reassessment

At 4 weeks:

• If no clinically significant response to antipsychotic at adequate dose, taper and discontinue 1
• Reassess with quantitative measures 1

Ongoing:

• Monitor for side effects; if clinically significant, review risk-benefit and consider tapering 1
• Even with positive response, periodically discuss tapering with family/surrogate 1

Practical Algorithm Summary

1. Rule out RLS → If present, start gabapentin enacarbil (addresses both agitation and insomnia)
2. If no RLS and severe agitation → Start risperidone 0.25-0.5 mg OR brexpiprazole 0.5-1 mg
3. For persistent insomnia despite agitation control → Add eszopiclone 1-2 mg OR lemborexant 2.5 mg at bedtime
4. Titrate antipsychotic to minimum effective dose over 1-2 weeks
5. Reassess at 4 weeks with quantitative measures; discontinue if ineffective

Important Caveats

• Brexpiprazole is maintenance therapy, not PRN; requires daily dosing 5
• Drug interactions: Brexpiprazole is metabolized by CYP2D6/3A4; adjust dose with strong inhibitors/inducers 5
• Cognitive enhancers: If not already on cholinesterase inhibitors or memantine, consider adding as they show moderate efficacy for BPSD 4
• Avoid benzodiazepines as primary treatment; small subgroup analysis showed less robust response 6
• The combination approach (antipsychotic + hypnotic) is pragmatic for dual severe symptoms but increases polypharmacy risks—monitor closely